Lantheus wins FDA approval for TauklariFY Alzheimer’s tau PET imaging agent

PUBT · 2d ago
Lantheus wins FDA approval for TauklariFY Alzheimer’s tau PET imaging agent
  • FDA cleared TAUKLARIFY (florquinitau F 18), a tau PET imaging agent for adults with cognitive impairment being evaluated for Alzheimer’s disease.
  • Label limits use to identifying tau neurofibrillary tangle pathology; not established for evaluating non-Alzheimer’s tauopathies.
  • Lantheus plans to assess a path to broader commercial availability while continuing to support Alzheimer’s therapeutic programs via its Pharma Solutions unit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.